ORPHA:93126
Pauci-immune glomerulonephritis
Publications
1,104
Trials
0
Interventional, condition-specific
Researchers
1,084
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare small vessel vasculitis associated with rapidly glomerulonephritis (GN) and clinically characterized by renal manifestations such as urinary abnormalities (hematuria and/or proteinuria) and hypertension leading to renal failure within days or weeks, and distinguished by the absence of immune deposits on immunofluorescent microscopy. The disease can occur as a renal-limited disease or as a component of systemic necrotizing small-vessel vasculitis.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019641
- UMLS:C0343196
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,104 matched papers (824 in last 10 years) Source
- Phenotype characterisedPresent
37 HPO annotations (e.g. Renal insufficiency; Proteinuria; Glomerular sclerosis) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 121 for broader category glomerulonephritis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
37
Associated phenotypes · MONDO:0019641
- Renal insufficiency
- Proteinuria
- Glomerular sclerosis
- Hoarse voice
- Abnormality of the upper respiratory tract
Showing 5 of 37 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,104
1,104 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,104 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
824 in the last 10 years · low confidence
Phrase hits: 1,104 · MeSH hits: 0
Who's working on it?
1,084
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Lee SW5 papers · 2025
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Papers in Europe PMC - 02Lionaki S5 papers · 2025
Department of Nephrology and Transplantation Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Papers in Europe PMC - 03Park YB5 papers · 2025
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Papers in Europe PMC - 04Geetha D4 papers · 2026
Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Papers in Europe PMC - 05Ha JW4 papers · 2025
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Papers in Europe PMC - 06Kronbichler A4 papers · 2026
Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria.
Papers in Europe PMC - 07Liapis G4 papers · 2025
1 Department of Pathology, Medical School, National and Kapodistrian University of Athens, Laiko Hospital, Athens, Greece.
Papers in Europe PMC - 08Kalogeropoulos P3 papers · 2025
Department of Nephrology and Transplantation Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Papers in Europe PMC - 09Marinaki S3 papers · 2024
Department of Nephrology and Transplantation Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Papers in Europe PMC - 10Song JJ3 papers · 2025
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 121 trials are registered for glomerulonephritis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
121 interventional trials matched glomerulonephritis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: glomerulonephritis
121
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06889948·RECRUITING·The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland
Conditions: Kidney Failure · Paraproteinemias · Glomerulonephritis·Matched via name phrase
- NCT05517980·NOT YET RECRUITING·Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
Conditions: Glomerulonephritis·Matched via name phrase
- NCT06295770·RECRUITING·Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
Conditions: Fibrillary Glomerulonephritis·Matched via name phrase
- NCT06858319·RECRUITING·Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Conditions: Kidney Diseases · Kidney Diseases, Chronic · Urological Diseases · Glomerulonephritis·Matched via name phrase
- NCT06676384·RECRUITING·Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
Conditions: IgA Nephropathy · Renal Insufficiency, Chronic · IgA Vasculitis · IGA Glomerulonephritis·Matched via name phrase
- NCT06623877·NOT YET RECRUITING·Using Renal Elastography Measurements for Evaluation of Glomerulonephritis Patients
Conditions: Evaluation of Biopcy Proven Glomerulonephritis Patients by Renal Shear Wave Elastography·Matched via name phrase
- NCT07203404·RECRUITING·A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
Conditions: SLE · LN · ANCA Associated Vasculitis · ANCA-Associated Glomerulonephritis·Matched via name phrase
- NCT04662723·RECRUITING·Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
Conditions: Glomerulonephritis · Immunoglobulin A Nephropathy·Matched via name phrase
- NCT06528015·NOT YET RECRUITING·Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy
Conditions: Glomerulonephritis, IGA · Probiotics · Budesonide·Matched via name phrase
- NCT00977977·RECRUITING·Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Conditions: Nephrotic Syndrome · Proteinuria · Autoimmune Disease · Glomerular Disease·Matched via name phrase
- NCT07730632·NOT YET RECRUITING·Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)
Conditions: IgAN - IgA Nephropathy · Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) · C3 Glomerulopathy (C3G) · Primary Membranous Nephropathy·Matched via name phrase
- NCT07389499·NOT YET RECRUITING·A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
Conditions: IgA Nephropathy (IgAN) · Membranous Nephropathy · ANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN) · Refractory Podocytopathy·Matched via name phrase
- NCT05996731·RECRUITING·Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
Conditions: Atypical Hemolytic Uremic Syndrome · Membranoproliferative Glomerulonephritis · Autosomal Dominant Polycystic Kidney · Healthy·Matched via name phrase
- NCT07746895·RECRUITING·Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
Conditions: C3 Glomerulopathy (C3G) · Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)·Matched via name phrase
- NCT06047171·RECRUITING·Rescue of Nephrons With ALE.F02 (RENAL-F02)
Conditions: Glomerulonephritis Rapidly Progressive·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Pauci-immune glomerulonephritis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Pauci-immune glomerulonephritis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Pauci-immune glomerulonephritis"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"glomerulonephritis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1104) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T04:07:26.205Z
